A Study of Subcutaneous At Home Administration of Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2-positive (HER2+) Early Breast Cancer (eBC)
Clinical trial NCT01926886 · COMPLETED
Trial details
- NCT number
- NCT01926886
- Sponsor
- Hoffmann-La Roche
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2013-11-19
- Primary completion
- 2015-09-04
- Enrollment
- 102
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.